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Lymphomatoid granulomatosis (LG) is a very rare, Epstein-Barr viruseassociated lymphoproliferative
disorder of B cells. Prognosis is poor, particularly after relapse and no curative treatment exists. We report the
results of high-dose therapy and autologous stem cell transplantation (ASCT) or reduced-intensity condi-
tioning and allogeneic stem cell transplantation (alloSCT) in patients with multiply relapsed LG. A European
Group for Blood and Marrow Transplantation survey identiﬁed 10 patients who had received 9 ASCT and 4
alloSCT. All patients had active disease at the time of transplantation. With a median follow-up of 5.1 (range,
1.4 to 6.3) years, 6 patients are alive and disease-free. Two ASCT patients died of septicemia early after
transplantation, and 1 committed suicide after being in continuous complete remission 19 months after ASCT.
Another patient allografted 4 years after ASCT remained disease-free but died of severe graft-versus-host
disease 3 months after alloSCT. High-dose therapy followed by ASCT and alloSCT are effective therapeutic
options and should be considered in all patients with refractory and multiply relapsed LG.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Lymphomatoid granulomatosis (LG) is a very rare,
Epstein-Barr virus (EBV)-driven B cell lymphoproliferative
disorder ﬁrst described as a distinct clinicopathological
entity by Liebow in 1972 [1]. At diagnosis, the majority of
patients are between 40 and 60 years of age with a deﬁnite
male preponderance. Immunocompromised patients are
more likely to develop LG, probably because cellular immu-
nodeﬁciency compromises EBV elimination. Three histolog-
ical grades have been described, depending on the number of
EBV-positive, CD-20 positive, large atypical B cells in relation
to reactive tissue. Whereas grade 1 lesions contain very few
and grade 2 lesions contain only scattered EBV-positive cells,
grade 3 lesions are characterized by sheets of large atypical
cells showing a high propensity to transform into diffuse
large B cell lymphoma [2]. Because of lung involvement inedgments on page 1524.
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of breath in combination with B symptoms, such as fever,
night sweats, and weight loss. The skin, kidneys, liver, and
the central nervous system are affected in about one third of
the patients, although involvement of lymph nodes or spleen
is rare. In older series, median survival of patients with LG
was under 2 years [3,4]. Patients with grade 1 or 2 lesions
may achieve durable remissions with corticosteroids and
interferon-alpha [5]. Dunleavy et al. investigated the use of
interferon-alpha in 28 patients with grade 1/2 disease and
achieved a 5-year progression-free survival of 56%. In
24 patients with grade 3 disease, progression-free survival
was 40% with dose-adjusted etoposide, doxorubicin,
cyclophosphamide, vincristine, prednisone  Rituximab
(DA-EPOCHR) with a median follow up of 28 months [6].
Despite a number of case reports, there are no reliable data
available if aggressive ﬁrst-line therapy, including combina-
tion chemotherapy with or without rituximab, can improve
outcome of patients with advanced disease as recently
reviewed [6-8]. Patients with relapsed disease often
demonstrate higher histologic grades and carry a very bad
prognosis with no curative approach having been described.
Because case reports of high-dose therapy followed by
autologous stem cell transplantation (HDT/ASCT) [9,10] or
allogeneic stem cell transplantation (alloSCT) [11] indicated
Table 1
Patients Characteristics
Patient Age*/
Gender
Stagey/Grade Sites of Diseasey/Yr
of Diagnosis
Lines of Therapy Preparatory Regimen Transplant/Time from
Diagnosis to
Transplantation (mo.)
Disease
Statusy
Best Response
after
Transplantation
Relapse Outcome
1 38/F IV A/3 Lung/2005 R-CHOP
R-I, MTX, E
BEAM Auto/7 PR PR Yes Received second auto
Z-BEAM Auto Relapse CR No A&W, d þ1456
2 48/M IE B/1 Lung/2007 Pred
R
R-CHOP
BEAM Auto/16 SD Autopsy: no
evidence of LG
No Died, d þ8: septicemia, VOD
3 37/F IV/not known Lung, liver, lymph nodes/2004 CHOP
DHAP
BEAM Auto/7 PR CR Yes NA
ICE FM Allo NE NA No Died, d þ1567: GvHD
4 53/F IV B/2 Lung, liver, lymph nodes/2007 Cy-Dex
R-CHOP
DHAP
a-IFN
HD-Cy
FBC12 Auto/9 SD CR No A&W, d þ1864
5 31/F II A/not known Lymph nodes/2002 V-CAMP
R-ICE
FBC Allo/52 PR CR No A&W, d þ1554
6 19/M IV A/3 Bone marrow, lymph nodes/2001 COPADM-COPAD
R
DHAP-VIM-
DHAP
BEAM Auto/52
FM18 Allo PR CR No A&W, d þ2119
7 34/M IV B/2 Lung, CNS/2004 R
HD-MTX
AraC16
FM18 Allo/13 PD not known No A&W, d þ2314
8 31/M IV A/2/3 Lung/2000 Pred
Cy
CHOP
BEAM5 Auto/10 PR CR No Died, d þ576: suicide
9 53/M IV B/2/3 Lung/2005 R-CHOP
ASHAP
TMC Auto/5 PD PD not known Died, d þ9:
PD, sepsis
10 49/F IV B/1 Lung, liver, CNS, adrenals, kidney/2011 R-CHOP
MTX
R-IE, AraC
TC/TBI Auto/5 PR PR No A&W, d þ502
R indicates rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; I, ifosfamide; MTX, methotrexate; E, etoposide; BEAM, BCNU, etoposide, cytosine-arabinoside, melphalan; Z-BEAM, ZevalinþBEAM; Pred,
prednisone; DHAP, dexamethasone, cytosine-arabinoside, adriamycin, methotrexate, prednisone; ICE, ifosfamide, cyclophosphamide, etoposide; Cy, cyclophosphamide; IFN, interferon; FBC, ﬂudarabine, busulphan, cyclo-
phosphamide; V-CAMP, vincristine, cyclophosphamide, adriamycin, methotrexate, prednisone; COPADM-COPAD, cyclophosphamide, vincristine, prednisone, doxorubicin, dexamethasone, methotrexate; VIM, VP-16, ifosfa-
mide, methotrexate; AraC, cytosine-arabinoside; ASHAP, adriamycin, solumedrol, cytosine-arabinoside, platinum; FM, ﬂudarabine, melphalan; TMC, thiotepa, melphalan, carboplatinum; TC/TBI, thiotepa, cyclophosphamide,
total body irradiation; A&W, alive and well; PR, partial remission; PD, progressive disease; d, day; GvHD, graft-versus-host disease; VOD, veno-occlusive disease.
* At time of transplantation.
y At diagnosis.
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K. Siegloch et al. / Biol Blood Marrow Transplant 19 (2013) 1514e15291524that patients with LG might beneﬁt from these procedures,
we aimed to collect all cases of autologous and allogeneic
transplantation reported to the EBMT to gain better insight
into the therapeutic impact of transplantation in this rare
disease.
PATIENTS AND METHODS
The European Group for Blood and Marrow Transplantation (EBMT) is
a voluntary organization currently comprising 545 transplantation centers.
All member centers are required to report all new hematopoietic stem cell
transplantations and follow-up data once per year. The LymphomaWorking
Party is responsible for data validation to ensure the quality of data. Because
LG is not listed as a distinct histological entity on case report forms, we
invited all EBMT centers to contribute data on their patients with
a conﬁrmed diagnosis of LG as deﬁned by the WHO classiﬁcation [2].
We identiﬁed 10 patients who had undergone 13 (9 autologous and 4
allogeneic) transplantations.All centers completedanextensivequestionnaire
for each eligible patient. Data for individual patients were derived both from
the EBMT database and the questionnaires sent out to the centers. Follow-up
questionnaires were sent to obtain missing data. Informed consent was ob-
tained locally according to regulations applicable at the time of trans-
plantation. After January 2003, EBMTcenters were required to obtainwritten
informed consent before data registration. In addition to the European cases,
we updated a case from Canada, which had previously been published [9].
RESULTS AND DISCUSSION
The major patient characteristics, lines of treatment, and
outcomes are summarized in Table 1. The patient cohort
ﬁnally consisted of 5 females and 5 males, ages between 19
and 53 years at the time of transplantation. Eight of 10
patients had been diagnosed with stage IV disease; the lungs
were the most frequently involved extranodal site (8 of 10
patients) but involvement of liver, CNS, kidneys, adrenals,
and bone marrow was also described. All patients had
received at least 2 lines of therapy before transplantation,
including rituximab in 7 patients. The median time interval
from diagnosis to stem cell transplantation was 9.5 (range, 5
to 52) months. All patients had active disease at the time of
stem cell transplantation: 6 patients were in partial remis-
sion immediately before their ﬁrst transplant, 2 had stable
disease, and 2 presented with progressive disease. Eight
patients received HDT/ASCT as their ﬁrst transplantation; 1
of these patients (patient 1) received a second autologous
transplant after HDT including ibritumomab tiuxetan
(Zevalin), another patient (patient 6) had a planned double
transplant procedure: BEAM/ASCT was followed by reduced-
intensity conditioning (RIC) and alloSCT from a matched
unrelated donor. Three more patients (patients 3, 5, 7)
received allografts after RIC, 1 of them because of relapse
after HDT/ASCT (patient 3). The stem cell donor was an HLA-
matched sibling in 1 and a matched unrelated donor in the
remaining 2. Five of the 8 ASCT patients received their
transplantation after BEAM, the other patients received other
HDT including thiotepa, melphalan, and carboplatinum;
ﬂudarabine, busulfan and cyclophosphamide; or total body
irradiation in combination with thiotepa and cyclo-
phoshamide. All conditioning regimens before allogeneic
transplantation were of reduced intensity (see Table 1).
With a median follow up of 5.1 (range, 1.4 to 6.3) years for
surviving patients, 6 of 10 patients are alive with no evidence
of disease. Notably, only 2 patients relapsed after trans-
plantation; 1 of these patients is in continuous complete
remission for almost 4 years after a second ASCT, the other
patient died 3 months after allogeneic transplantation from
severe graft-versus-host disease of the gut; at this time,
histology was diffuse large B cell lymphoma rather than LG.
Two ASCT patients died of septicemia on days þ8 or þ9
after transplantation; no evidence of LG was found at theautopsy in 1 of these patients, the other patient had evidence
of progressive disease after ASCT. Unfortunately, patient 8
committed suicide 19 months after ASCT while being in
remission from LG.
In summary, 6 patients remain alive and well 5.1 (1.4 to
6.3) years after HDT/ASCT or RIC/alloSCT (3 patients each).
One patient committed suicidewith no evidence of LG at that
time and 2 patients died of transplantation-related compli-
cations (septicemia) early after HDT/ASCT. One of these
patients was reported as being refractory to salvage therapy
before HDT/ASCT. A correlation between time from diagnosis
or status of disease before transplantation and outcome does
not exist, possibly due to small numbers. Given the number
and the nature of prior therapies (including rituximab in 7
patients) and the status of disease before transplantation, we
consider the results achieved with HDT/ASCT and/or RIC/
alloSCT promising in a disease believed to carry a poor
prognosis at diagnosis but certainly so in multiply relapsed
or refractory patients.
This study represents the ﬁrst, albeit small, series of
patients who underwent transplantation for LG, a disease so
exceedingly rare that until now, only case reports for ﬁrst-
line and certainly for treatment of relapsed cases have
been published.
With only 10 patients reported here, our series may be
biased by over-reporting of successful cases, although we
explicitly asked EBMT members to report all cases from their
institutions. It also is not possible to decide if autologous or
allogeneic transplants should be preferred or to comment on
details of the transplant procedure, such as the best choice of
the preparatory regimen, donor selection, or graft-versus-
host disease prophylaxis for allografted patients. Nonethe-
less, HDT/ASCT and RIC/alloSCT showed promising results in
this small series of advanced LG patients and should be
considered for relapsed and otherwise refractory patients ﬁt
enough to undergo any of these procedures.
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Werecently demonstrated that expression of a-defensins, themajor antimicrobial peptides produced byPaneth
cells, was severely suppressed in mice with graft-versus-host disease (GVHD). In this study, we found that
antibacterial lectin, regenerating islet-derived IIIg (RegIIIg) was upregulated in villous enterocytes, thus
demonstrating the reciprocal control of enteric antimicrobial proteins in GVHD. Upregulation of RegIIIg was
mediated by a mechanism independent upon radiation-induced intestinal tract damage. MyD88-mediated
signaling in intestinal epithelium was required for RegIIIg upregulation in GVHD and antibiotic therapy
downregulated RegIIIg expression. These results suggest that MyD88-mediated sensing of the intestinal
microbes disregulated in GVHD induces RegIIIg upregulation in GVHD and argue a role for RegIIIg in the
pathogenesis of GVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION peptides. Among them, a-defensins are the most potent
Allogeneic hematopoietic stem cell transplantation,
a curative therapy for a number of hematologic diseases, is
complicated by graft-versus-host disease (GVHD). Particu-
larly, intestinal GVHD is critical for determining the outcome
of allogeneic bone marrow transplantation (BMT) [1].
Recently, regenerating islet-derived 3a (RegIIIa) was identi-
ﬁed as a speciﬁc biomarker for intestinal GVHD in humans
using a large-scale and quantitative proteomic discovery
approach [2,3]. Reg genes constitute a multigene family,
which is categorized into 4 subclasses. RegIIIg, a homologue
of human RegIIIa in mice, is preferentially expressed in the
small intestine. RegIIIg have canonical C-type lectin domains
that bind to the peptidoglycan, which is an essential
component of the bacterial cell wall and, thus, has direct
antimicrobial activity, speciﬁcally against Gram-positive
bacteria and protects the epithelial barrier function of the
intestinal mucosa [4].
The intestinal microbial communities are actively regu-
lated by Paneth cells through their secretion of antimicrobialantimicrobial peptides that account for 70% of the bactericidal
peptide activity released from Paneth cells [5,6]. We recently
found that Paneth cells were targeted by GVHD, resulting in
marked reduction in the expression of a-defensins [7]. Thus, it
is puzzling why blood levels of RegIIIa levels are elevated,
whereas a-defensins are downregulated, in GVHD. In this
study,weevaluatedenteric expressionofRegIIIg at the cellular
level in mouse models of BMT and found that the major
producers of RegIIIgwere villous enterocytes, not Paneth cells,
in GVHD. Upregulation of RegIIIg in GVHD was dependent
upon MyD88-mediated sensing of the intestinal microﬂora.
MATERIAL AND METHODS
Mice
Female C57BL/6 (B6: H-2b), B6D2F1 (H-2b/d), B6-Ly5.1 (H-2b, CD45.1þ),
BALB.B (H-2b), and C3H.Sw (H-2b) mice were purchased from Charles River
Japan, KBT Oriental, or Japan SLC. B6-background Myeloid differentiation
factor 88 (MyD88)-deﬁcient (MyD88/) mice [8] were kindly provided by
Dr. Kiyoshi Takeda at Osaka University. All animal experiments were per-
formed under the auspices of the Institutional Animal Care and Research
Advisory Committee.
BMT
Mice underwent transplantation as previously described [9]. In brief,
after lethal X-ray total body irradiation delivered in 2 doses at 4 hour
intervals, mice were intravenously injected with 5  106 T celledepleted
bonemarrow (TCD-BM) cells with or without 2106 splenic Tcells on day 0.
Isolation of T cells and T cell depletion were performed using the T cell
isolation kit and anti-CD90-MicroBeads, respectively, and the AutoMACS
(Miltenyi Biotec, Tokyo, Japan) according to the manufacturer’s instructions.
